Showing 1 - 10 of 15 Lung Cancers
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Elizabeth Soriano

Phone: 713.441.14203

This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cispla ... Read more >

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Jose Cruz

Phone: 713.441.4457

This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutation ... Read more >

A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator:

Phone:

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with ... Read more >

A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR rate of pembrolizumab as a single agent. Additionally the dynami ... Read more >

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatmen ... Read more >

A151216 - Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery ALCHEMIST

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Daniel (cancer) Le (cancer)

Phone: 346.238.5655

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in diffe ... Read more >

Determine early biomarkers involved in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Mary Rose Silvas

Phone: 713.441.1952

The purpose of this exploratory biomarker study is to further our understanding of the role of cancer stem cells (CSCs) and other biomarkers in the progression of COPD to lung cancer by examining the CSC population and other related biomarkers, ... Read more >

Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3 ... Read more >

Lung Retrospective Protocol

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The purpose of this exploratory biomarker study is to further our understanding of the role of CSCs in lung cancer metastasis by examining the CSC population in metastatic tissue. ... Read more >

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator:

Phone:

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand t ... Read more >

Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator: Daniel (cancer) Le (cancer)

Phone: 346.238.5655

The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >

PILOT STUDY TO CHARACTERIZE THE COMPOSITION/DIVERSITY OF THE GUT MICROBIOME IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER RECEIVING STANDARD OF CARE CHECKPOINT BLOCKADE IMMUNOTHERAPY

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

The purpose of this pilot study is to characterize the composition/diversity of the gut microbiome in patients with metastatic NSCLC who are receiving standard of care checkpoint blockade immunotherapy. This study will lay the groundwork for lar ... Read more >

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Daniel (cancer) Le (cancer)

Phone: 346.238.5655

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >

SMARTPLUS-106: Debio 1143 a SMAC Mimetic in Combination with Nivolumab in Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial

Status: Enrolling

Investigator: Kirk Heyne

Study Coordinator:

Phone:

The purpose of this study is to investigate nivolumab combined with Debio 1143. The study will focus on subjects with specific solid tumors for whom tumors were previously treated with anti-PD-1/PD-L1 therapy as a single therapy (or when used wi ... Read more >